Item 5. Market for Registrant’s Common Equity
Item
5. Market for Registrant’s Common Equity and Related Stockholder Matters and Issuer Purchases of Equity Securities
Market
Information
Our
common stock is traded under the symbol “KOAN” on the OTCQB. Only a limited market exists for our securities. There is no
assurance that a regular trading market will develop, or if developed, that it will be sustained. Therefore, a shareholder may be unable
to resell his securities in our company.
The
following tables set forth the range of high and low bid information for our common stock for the each of the periods indicated. These
quotations reflect inter-dealer prices, without retail mark-up, mark-down or commission and may not necessarily represent actual transactions.
Fiscal
Year Ending December 31, 2021
Quarter Ended
High $
Low $
March 31, 2021
.93
.11
June 30, 2021
.67
.23
September 30, 2021
.49
.34
December 31, 2021
.42
.20
Fiscal
Year Ending December 31, 2020
Quarter Ended
High $
Low $
March 31, 2020
.20
.03
June 30, 2020
.27
.05
September 30, 2020
.19
.07
December 31, 2020
.20
.08
On
April 14, 2022, the last sales price per share of our common stock was $.11
Holders
of Our Common Stock
As
of April 14, 2022, we had 47,796,859 shares of our common stock issued and outstanding, held by approximately 164 shareholders
of record at our transfer agent, with approximately 47 additional shareholders holding our shares in street name.
Dividends
We
currently intend to retain future earnings for the operation of our business. We have never declared or paid cash dividends on our common
stock, and we do not anticipate paying any cash dividends in the foreseeable future.
In
the event that a dividend is declared, common stockholders on the record date are entitled to share ratably in any dividends that may
be declared from time to time on the common stock by our board of directors from funds legally available.
There
are no restrictions in our articles of incorporation or bylaws that restrict us from declaring dividends. The Nevada Revised Statutes,
however, do prohibit us from declaring dividends where, after giving effect to the distribution of the dividend:
1.
We
would not be able to pay our debts as they become due in the usual course of business; or
20
2.
Our
total assets would be less than the sum of our total liabilities, plus the amount that would be needed to satisfy the rights of shareholders
who have preferential rights superior to those receiving the distribution.
Securities
Authorized for Issuance under Equity Compensation Plans
On
March 19, 2019, our Board of Directors adopted the 2019 Equity Incentive Plan (the “Plan”). The purpose of the Plan is to
attract and retain the best available personnel for positions of substantial responsibility with us, to provide additional incentive
to employees, directors and consultants, and to promote our success. Under the Plan, we are currently able to issue up to an aggregate
total of 10,000,000 incentive or non-qualified options to purchase our common stock, stock awards and other offerings.
Equity
Compensation Plans as of December 31, 2021
Equity Compensation
Plans Approved by
the Shareholders
Number of
Securities
to
be issued
upon
exercise
of
outstanding
options
Weighted-
average
exercise
price
of
outstanding
options
Number of
Securities
remaining
available
for future
issuance under
equity compensation
plans
(a)
(b)
(c)
2019 Equity
Compensation Plan
-
-
10,000,000
Other Equity Compensation (restricted stock awards)
-
-
-
Total
-
-
10,000,000
Recent
Sales of Unregistered Securities
From
December 1, 2020 through March 15, 2021, we sold units priced at $25,000 per unit where each unit consisted of (i) an 8.0% Note in
the principal amount of $25,000 convertible into Common Stock (the “Note) and (ii) a warrant at an exercise price of $0.15 for
the purchase of 83,333 shares of the Company’s Common Stock (the “Warrant”).
We
sold 90 Units for total proceeds of $2,265,000. After paying finder fees of $187,450 to our placement agent, we netted $2,077,550, which
will be used for working capital.
In
addition, we also entered into subscription agreements in connection with an equity placement offering of a maximum of $2,000,000 in
units (the “Equity Units”) where each Equity Unit consists of one share of Common Stock at a purchase price of $0.15 and
a warrant to purchase 0.5 share(s) of Common Stock at an exercise price of $0.225 per share. We sold 6,983,333 Equity Units for total
proceeds of $1,047,500. After paying finder fees of $100,763 to our placement agent, we netted $946,737, which was used to pay off the
remaining convertible note debt and will also be used for working capital.
During
the six-month ended June 30, 2021, the company issued a total of 2,868,025 shares of common stock to vendors for compensation and services
rendered.
During
the third quarter of 2021 the company issued a total of 716,554 shares of common stock to vendors for compensation and services rendered.
During
the fourth quarter of 2021 the company issued a total of 59,171 shares of common stock to vendors for compensation and services rendered.
These
securities were issued pursuant to Section 4(2) of the Securities Act and/or Rule 506 promulgated thereunder. The holders represented
their intention to acquire the securities for investment only and not with a view towards distribution. The investors were given adequate
information about us to make an informed investment decision. We did not engage in any general solicitation or advertising. We directed
our transfer agent to issue the stock certificates with the appropriate restrictive legend affixed to the restricted stock.
Item
6. Selected Financial Data
Not
required under Regulation S-K for “smaller reporting companies.”
Item
7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Overview
We
continue to make headway with our strategic objectives to position our company for long-term growth. We are laying the groundwork to
scale with key sales channels now operational, including our recently launched Direct-to-Consumer sales platform.
Working
closely with industry-leading sales, marketing, and logistics partners for our flagship Koan Cordials product line, we have built a multi-channel
distribution strategy. Following our launch into the retail chain and the opening of our e-commerce sales platform, we are turning our
focus to three critical areas - education, targeted marketing, and controlling the sales process.
21
We
took an ambitious approach to our original dispensary rollout and were met with a high amount of interest in our product, reflected by
the roughly 80 dispensaries who requested sample kits. While the reception was very positive, we found reluctance for the dispensaries
to acquire new brands particularly with the advent of the Delta variant of COVID. While the recent threat of a potential COVID-related
retail lockdown in California slowed our progress on the dispensary front, we expect to gain momentum in the retail market as it starts
to open up again by revisiting each of these dispensaries. Many of those initial dispensary requests have been followed up by commitments
to buy once they begin bringing new brands into the stores.
We
believe the careful nurturing of our brand is one of our most important responsibilities as managers of Resonate Blends. Since nobody
knows our product better than we do, we made the decision to bring the sales process in-house versus having an external salesforce. We
are confident this move will have an immediate positive impact on revenues and allow our team to better control the narrative within
the retail network in California.
We
plan to soon offer several packaging variations for our Cordials based on dispensary and consumer feedback. In addition to our Cordial
3-pack, we plan to soon have a single-packaged Cordial, and a multi-blends sampler SKU. We believe having these options encourages the
consumer to try more blends and will allow us to do more sampling and upselling promotions. We are also designing a multi-dose bottle
which will be more cost-effective for those who use our blends daily. Together, these new packaging configurations should help accelerate
our sales revenue by providing consumers convenient options. We also expect to introduce two new formulations and other unique product
lines that will showcase our focus on continual product development and brand innovation within our family of Koan products.
While
we expect to ramp up our retail footprint in the quarters ahead, we did make several key entry points to dispensaries. To that end, we
recently announced nine (9) new California One Plant dispensaries and are working closely with them to co-market the Cordials across
their vast network. The collaboration and communication with the One Plant team is deep and we will be exploring creative and unique
marketing efforts at two of their flagship stores. We are an approved vendor for the Joy Reserve located in the Westfield Centre in Union
Square (San Francisco). The Joy Reserve is the first cannabis dispensary located in a mall setting and offers consumers education and
guidance to select the best products for their lifestyles.
We
just launched with The Joy Reserve dispensary, which is focused on bringing a better understanding of the many benefits of cannabis and
how to safely pick quality products such as the Koan Cordials. This unique showcase will be used to educate consumers about plant-based
wellness with an open browsing floor, free consultations and workshops. We feel this setup is ideal to introduce consumers to our Cordials
and are excited to participate in this groundbreaking approach.
22
Marketing
and branding are core components of our targeted customer acquisition strategy. We have invested significantly to our overall marketing
efforts, including cannabis conferences, social media outreach, Search Engine Optimization (SEO), and marketing events with our dispensary
partners. We recently consolidated our digital marketing to the Flower Agency, a full digital marketing agency that assists lifestyle,
wellness and cannabis brands with customer acquisition, awareness and re-engagement. Importantly, our patent-pending Koan Cordials, the
world’s first cannabis-infused cordial, are starting to gain national recognition from cannabis industry leaders. We expect to
see a significant uptick in press and other media mentions in the coming months.
We
are very encouraged with our Koan Cordials winning the show’s Gold Leaf Award for “Best New Brand of 2021” at the invitation-only
“Luxury Meets Cannabis Conference”. The Gold Leaf Awards honor those visionary crossover brands, retailers, and founders
that are going above and beyond both in and outside of the cannabis space — across beauty, skincare, food/beverage, and everyday
wellness sectors. The interest since this award announcement for potential acquisitions and new state expansion has been extremely gratifying.
Koan Cordials also won a Bronze 2021 Clio Cannabis Award for brand
design in the packaging category. The Clio Awards is an annual global award program recognizing innovation and creative excellence in
advertising, design and communication. Clio Cannabis recognizes and elevates creative contributions from top design talent in the rapidly
growing cannabis market.
With
an established statewide infrastructure in California for manufacturing, distribution and sales, we are well-equipped to make progress
with our go-forward focus on revenue generation. We are uniquely positioned to be a positive disruptive force in the wellness/lifestyle
segment of the industry built on a growing body of proprietary IP, and we firmly believe that value-added brands are the future of the
Cannabis industry. Over the long-term, we believe that cannabis, as a part of the wellness lifestyle, will become the largest segment
in the burgeoning industry and we plan to be one of the leaders in this segment.
Results
of Operations for the Years Ended December 31, 2021 and 2020
Revenues
We
have generated $27,031 in revenues for the year ended December 31, 2021, as compared with no sales for the year ended December
31, 2020 on our current product line, and also no sales from the discontinued operations of our sold subsidiary, Textmunication, Inc.,
for the years ended December 31, 2021 and 2020, respectively. We have launched our first line of six Cordial products in California and
we have started to generate revenues from the sale of these products.
We
anticipate increased revenues on our six Cordials for the rest of 2022. We anticipate a rollout of new packaging configurations by early
Q2 2022 for our Cordials; to include both a one-pack and a multi-dose bottle which is expected to bring the cost per dose
down considerably. We also plan on launching additional Cordial formulations by Q2 2022 and a new line of edibles in
mid-2022, which we anticipate will contribute to increasing our revenues. As we have just launched our products,
however, it may take some time for the markets to react, gain traction and result in brand awareness among our customers. There can
be no assurances, however, that customers will positively react to our products.
Operating
Expenses
Our
operating expenses were $2,534,577 for the year ended December 31, 2021, as compared with $1,813,958 for the year ended December
31, 2020.
The main drivers for
the overall increase in operating expenses in 2021 was our focus on advertising to support our planned growth and non-cash items related
to broker and employee equity compensation. We paid both cash fees and stock compensation to a broker on our Private Placement Memorandum
in Q1.
Within the operating
expenses, there were a variety of increases, the largest of which was an increase in non-cash management fees of $400,349 as a result
of issuing stock in 2021 in settlement of accrued but unpaid management and employee salaries in 2020. We hope that to avoid these settlement
expenses for 2022 and compensate employees with available cash on hand. However, if we are forced to defer salaries and settle with shares
for employees this year, due to a lack of funds, we should expect our non-cash compensation expense in 2022 to resemble that of 2021.
In 2021 and 2020, we
compensated a broker with combined share and cash compensation valued at $512,312 and $34,250, respectively for its services as placement
agent. We expect to incur similar broker expenses as long as we are dependent on additional financing for our operations, and we expect
that will be the case for the rest of 2022.
We spent $604,564 more
on advertising in 2021 than in 2020. This money was used to introduce our Koan Cordials to the California retail channel, perform Search
Engine Optimization (SEO), conduct Programmatic advertising, hire a professional agency to promote our Cordials on social media channels
and other general advertising methods. We believe our advertising efforts will pay dividends throughout 2022 as the awareness groundwork
has been established to educate the market on our family of Cordial formulations.
Professional fees increased
by $45,175 in 2021 compared with 2020. With more focus on operations, we have spent more on professional fees. We expect that professional
fees will increase in 2022 as we continue to ramp up operations.
General and administrative
expenses decreased by $520,409 in 2021 compared with 2020. This resulted from bringing several outside services in-house and not having
to address outstanding debt liabilities from our previous spin-out of Textmunication Holdings, Inc. in 2020. We expect general and administrative
expenses to remain fairly constant throughout 2022 due to internal changes we’ve implemented.
Other
Income
We
had other expenses of $2,346,362 for the year ended December 31, 2021 compared with other expenses of $143,113 for the year ended
December 31, 2020. Our other expenses for the year ended December 31, 2021 was mainly attributable to a loss on revaluation of derivative
liabilities.
23
Net
Income/Loss
We
had net loss of $4,873,056 for the year ended December 31, 2021, as compared with net loss of $1,941,274 for the year ended December
31, 2020. Our increased loss in 2021 is mainly from a lack of revenue, combined with increased advertising to support our growth and
significant non-cash expenses related to broker and employee equity compensation. We believe that our increased marketing activity and
compensating valuable employees and partners will pay off with increased brand exposure that we expect will generate more sales for the
upcoming year.
Liquidity
and Capital Resources
As
of December 31, 2021, we had total current assets of $269,518, consisting of $12,913 in cash, $10,830 in advances to suppliers and
$245,776 in Inventories. Our total current liabilities as of December 31, 2021 were $4,402,886. We had a working capital deficit
of $4,133,368 as of December 31, 2021, compared with a working capital deficit of $996,439 as of December 31, 2020.
Cash
Flows from Operating Activities
Operating
activities used $2,792,687 in cash for the year ended December 31, 2021, compared with cash used of $1,381,003 for the year ended
December 31, 2020. Our negative operating cash flow for the year ended December 31, 2021 was largely the result of our net loss, offset
mainly by the loss on derivative liabilities. Our negative operating cash flow for the year ended December 31, 2020 was largely the
result also of our net loss, offset mainly by share based compensation.
Cash
Flows from Investing Activities
Investing
activities used $36,047 in cash for the year ended December 31, 2021 while we used no cash on investing activities for the year
ended December 31, 2020.
Cash
Flows from Financing Activities
Cash
flows provided by financing activities during the year ended December 31, 2021 amounted to $2,727,322 compared with cash flows
provided by financing activities of $1,492,213 for the year ended December 31, 2020. Our positive cash flows for the year ended December
31, 2021 consisted of proceeds from issuance of common stock of $1,367,115, proceeds from Convertible notes payable of $1,865,000,
offset by payments of notes payable of $504,793. Our positive cash flows for the year ended December 31, 2020 consisted of proceeds
from issuance of common stock $1,011,113, proceeds from Convertible notes payable $850,100, offset by payments of notes payable of $369,000.
The
features of the debt instruments and payables concerning our financing activities are detailed in the footnotes to our financial statements.
We
are dependent on investment capital to continue our survival. We have raised money through convertible debt, almost always on unfavorable
terms. There is no guarantee that these small convertible loans will be available to us in the future or on terms acceptable to us.
We
also plan to raise money in the sale of our equity and debt securities. There can be no assurance of funds from these efforts or that
any other type of additional financing will be available to us on acceptable terms, or at all.
Going
Concern
As
of December 31, 2021, we have an accumulated deficit of $25,974,051. Our ability to continue as a going concern is contingent
upon the successful completion of additional financing arrangements and our ability to achieve and maintain profitable operations. While
we are expanding our best efforts to achieve the above plans, there is no assurance that any such activity will generate funds that will
be available for operations. These conditions raise substantial doubt about our ability to continue as a going concern. These financial
statements do not include any adjustments that might arise from this uncertainty.
Off
Balance Sheet Arrangements
As
of December 31, 2021, there were no off-balance sheet arrangements.
Critical
Accounting Policies
In
December 2001, the SEC requested that all registrants list their most “critical accounting polices” in the Management Discussion
and Analysis. The SEC indicated that a “critical accounting policy” is one which is both important to the portrayal of a
company’s financial condition and results, and requires management’s most difficult, subjective or complex judgments, often
as a result of the need to make estimates about the effect of matters that are inherently uncertain. Our critical accounting policies
are disclosed in Note 2 of our audited financial statements included in the Form 10-K filed with the Securities and Exchange Commission.
Recent
Accounting Pronouncements
No
new accounting pronouncements issued or effective during the fiscal year has had or is expected to have a material impact on the financial
statements.
24
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.